Literature DB >> 10752936

The National Eye Institute Visual Function Questionnaire: experience of the ONTT. Optic Neuritis Treatment Trial.

S R Cole1, R W Beck, P S Moke, R L Gal, D T Long.   

Abstract

PURPOSE: To describe the health-related quality of life, measured with the National Eye Institute Visual Function Questionnaire (NEI-VFQ), of patients several years after the onset of optic neuritis, according to their neurologic and visual status; to assess the relationship between the NEI-VFQ subscales and clinical measures of visual function; and to assess the internal consistency reliability of the NEI-VFQ subscales.
METHODS: The NEI-VFQ was administered to 244 patients 5 to 8 years after treatment for an episode of acute optic neuritis as part of the Optic Neuritis Treatment Trial. Visual acuity, visual field, contrast sensitivity, and color vision were measured at the same time as questionnaire completion.
RESULTS: The NEI-VFQ scores generally were lower than those reported for a disease-free group. Reported dysfunction was greater when multiple sclerosis was present and when visual acuity was abnormal, supporting the construct validity of the NEI-VFQ. Rank correlations between the NEI-VFQ subscales and clinical measures of visual function were moderate at best. Internal consistency reliability was generally high for most of the NEI-VFQ subscales.
CONCLUSIONS: These findings add support to the use of the NEI-VFQ as a valuable measure of self-reported visual impairment.

Entities:  

Mesh:

Year:  2000        PMID: 10752936

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  52 in total

1.  Relation between perceived driving disability and scores of vision screening tests.

Authors:  L J van Rijn; H Wilhelm; M Emesz; R Kaper; S Heine; S Nitsch; G Grabner; H J Völker-Dieben
Journal:  Br J Ophthalmol       Date:  2002-11       Impact factor: 4.638

2.  Associations among visual acuity and vision- and health-related quality of life among patients in the multicenter uveitis steroid treatment trial.

Authors:  Kevin D Frick; Lea T Drye; John H Kempen; James P Dunn; Gary N Holland; Paul Latkany; Narsing A Rao; H Nida Sen; Elizabeth A Sugar; Jennifer E Thorne; Robert C Wang; Janet T Holbrook
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-03-09       Impact factor: 4.799

3.  Quality of life in sarcoidosis: comparing the impact of ocular and non-ocular involvement of the disease.

Authors:  Leorey N Saligan; Grace Levy-Clarke; Tongtong Wu; Lisa J Faia; Keith Wroblewski; Steven Yeh; Robert B Nussenblatt; H Nida Sen
Journal:  Ophthalmic Epidemiol       Date:  2010-08       Impact factor: 1.648

Review 4.  Corticosteroids for treating optic neuritis.

Authors:  Robin L Gal; Satyanarayana S Vedula; Roy Beck
Journal:  Cochrane Database Syst Rev       Date:  2015-08-14

Review 5.  Corticosteroids for treating optic neuritis.

Authors:  S S Vedula; S Brodney-Folse; R L Gal; R Beck
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

6.  Ganglion cell loss in relation to visual disability in multiple sclerosis.

Authors:  Scott D Walter; Hiroshi Ishikawa; Kristin M Galetta; Reiko E Sakai; Daniel J Feller; Sam B Henderson; James A Wilson; Maureen G Maguire; Steven L Galetta; Elliot Frohman; Peter A Calabresi; Joel S Schuman; Laura J Balcer
Journal:  Ophthalmology       Date:  2012-02-23       Impact factor: 12.079

7.  Optic Neuritis Associated or Not with TNF Antagonists in Patients with Inflammatory Bowel Disease.

Authors:  Benjamin Alexandre; Yves Vandermeeren; Olivier Dewit; Tom Moreels; Nanne de Boer; Anjan Dhar; Chris Ziady; Ariella Bar-Gil Shitrit; Flavio Steinwurz; Njegica Jojic; Giuseppe Costantino; Benoit Bihin; Jean-François Rahier; Konstantinos H Katsanos
Journal:  J Crohns Colitis       Date:  2016-01-12       Impact factor: 9.071

Review 8.  Vision-specific instruments for the assessment of health-related quality of life and visual functioning: a literature review.

Authors:  Mary Kay Margolis; Karin Coyne; Tessa Kennedy-Martin; Timothy Baker; Oliver Schein; Dennis A Revicki
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

9.  Concordance between common dry eye diagnostic tests.

Authors:  J E Moore; J E Graham; E A Goodall; D A Dartt; A Leccisotti; V E McGilligan; T C B Moore
Journal:  Br J Ophthalmol       Date:  2008-09-09       Impact factor: 4.638

10.  The quality of life impact of peripheral versus central vision loss with a focus on glaucoma versus age-related macular degeneration.

Authors:  Keith Evans; Simon K Law; John Walt; Patricia Buchholz; Jan Hansen
Journal:  Clin Ophthalmol       Date:  2009-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.